RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Feb 19, 2013 - 1:22:36 AM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Continuing uncertainties surround anti-influenza drug

Jan 17, 2012 - 5:00:00 AM
The researchers conclude that there is an urgent need for independent research on both of these drugs. There is continuing uncertainty about their effects beyond the initial reduction in symptoms, mainly because full access to the data needed has still not been provided. We believe that until more is known about the mode of action of neuraminidase inhibitors health professionals, patients and other decision makers need to reflect on the findings of this review before making any decision about the use of the drug, concluded Jefferson.

 
[RxPG] Incomplete availability of data has hampered a thorough assessment of the evidence for using the anti-influenza drug oseltamivir, a Cochrane Review has found. However, after piecing together information from over 16,000 pages of clinical trial data and documents used in the process of licensing oseltamivir (Tamiflu) by national authorities, a team of researchers has raised critical questions about how well the drug works and about its reported safety profile. The new analysis shows inconsistencies with published reports, and describes possible under-reporting of drug-related side-effects in some published trial reports. While the drug did reduce the time to first alleviation of symptoms by an average of 21 hours, it did not reduce the number of people who went on to need hospital treatment. Results from the reanalysis of data also raise questions about how the drug works as an influenza virus inhibitor.

These finding are published in The Cochrane Library by an international team of researchers from Italy, Australia, USA, UK and Japan. It was funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme.

In line with World Health Organization (WHO) recommendations made in 2002, governments around the world have spent billions of dollars stockpiling neuraminidase inhibitors such as oseltamivir and zanamivir (Relenza). The agents' proposed mode of action is to limit the proliferation of viruses within an infected person, which in turn reduce the duration of a person's symptoms, and consequently reduce the chances of passing the disease to another person.

Led by Dr Tom Jefferson, a Cochrane review author and independent epidemiologist based in Rome, Italy, a team of researchers have obtained and analysed data on antiviral drugs, much of which has never been published, and evaluated the evidence that lay behind some of the statements. This latest Cochrane review focused primarily on oseltamivir because it is a commonly used and stockpiled drug and is on the list of WHO essential drugs. The Cochrane team were reluctant to base their research on the trials that have been published in scientific journals, because while many trials have been conducted around the world, only a few have been published.

We identified that a large number of studies, including data from 60% of the people who have been involved in randomised, placebo-controlled phase III treatment trials of oseltamivir have never been published. This includes the biggest treatment trial ever undertaken on oseltamivir that on its own included just over 1,400 people of all ages, says Jefferson. We are concerned that these data remain unavailable for scrutiny by the scientific community.

Although the team were able to access thousands of pages of data provided to national regulatory agencies and other bodies, they were only able to access a proportion of the data they needed to evaluate fully the effects of oseltamivir, despite requests to the drug's manufacturer, Roche.

When the team compared published data with the more complete unpublished trial records, they found inconsistencies in the published record of the trials. For example, while unpublished trial reports mentioned serious adverse events (some even classified as possibly related to oseltamivir), one of the two most cited publications makes no mention of such effects, and the other states ... there were no drug-related serious adverse events.

Jefferson and colleagues also found disparities in the numbers of influenza-infected people reported to be present in the treatment versus control groups of oseltamivir trials. The researchers believe that this imbalance may be caused by oseltamivir affecting antibody production. The disparity is important because in oseltamivir trials, primary efficacy outcomes were analyzed on the influenza infected subpopulation, but it is not clear that these groups were in fact comparable, says Jefferson.

The researchers conclude that there is an urgent need for independent research on both of these drugs. There is continuing uncertainty about their effects beyond the initial reduction in symptoms, mainly because full access to the data needed has still not been provided. We believe that until more is known about the mode of action of neuraminidase inhibitors health professionals, patients and other decision makers need to reflect on the findings of this review before making any decision about the use of the drug, concluded Jefferson.

Also published in this issue of The Cochrane Library is an updated systematic review of neuraminidase inhibitors for children only ('Neuraminidase inhibitors for preventing and treating influenza in children' by Wang et al). Dr David Tovey, Editor in Chief of The Cochrane Library notes that This review uses more standard review methods and only evaluates published studies. The two reviews therefore use different methods and this leads to differences regarding their findings, but some results are broadly similar to those presented in the review by Jefferson et al.



Related Latest Research News
Moderate to severe psoriasis linked to chronic kidney disease, say experts
Licensing deal marks coming of age for University of Washington, University of Alabama-Birmingham
Simple blood or urine test to identify blinding disease
Physician job satisfaction driven by quality of patient care
Book explores undiscovered economics of everyday life
Gene and stem cell therapy combination could aid wound healing
Solving the internet capacity crunch
Breathing new life into preterm baby research
Perceptions of the role of the state shape water services provision
UltraHaptics -- it's magic in the air

Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)